Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022

Rhea-AI Summary

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will release its second quarter 2022 financial results on August 10, 2022, before U.S. market open. A conference call will follow at 8:30 a.m. ET to discuss the results. The company focuses on developing innovative therapies, with three products currently available: Gvoke®, Keveyis®, and Recorlev®. Xeris aims to expand its product pipeline through proprietary formulation technologies.

Positive

• Xeris has three commercially available products: Gvoke®, Keveyis®, and Recorlev®.
• The company has a strong commitment to developing and commercializing innovative therapies.

Negative

• None.

Conference call and webcast at 8:30am ET

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing differentiated and innovative products across a range of therapies, today announced that the Company will release its second quarter 2022 financial results before the open of the U.S. financial markets on Wednesday, August 10, 2022. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.

To pre-register for the conference call please use this link: https://ige.netroadshow.com/registration/q4inc/11152/xeris-biopharma-second-quarter-2022-financial-results-call/. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Wednesday, August 24, 2022, at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 562978. In addition, a live audio of the conference call will be available as a webcast. To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com.

About Xeris Biopharma Holdings, Inc.

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005159/en/

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

312-736-1237

Source: Xeris Biopharma Holdings, Inc.

FAQ

When will Xeris Biopharma announce its Q2 2022 financial results?

Xeris Biopharma will announce its Q2 2022 financial results on August 10, 2022.

What time is the Xeris Biopharma conference call?

The conference call for Xeris Biopharma will be held at 8:30 a.m. ET on August 10, 2022.

What products does Xeris Biopharma currently offer?

Xeris Biopharma currently offers Gvoke®, Keveyis®, and Recorlev®.

What is Xeris Biopharma's growth strategy?

Xeris Biopharma focuses on developing and commercializing innovative therapies and expanding its product pipeline.